The Ohio State University

Ohio State Innovation Foundation

University of Michigan

University of Minnesota

Aalborg University

Ramiro Garzon

Carlo M Croce

George A Calin

Adrienne M Dorrance

Bruce Robert Blazar

Robert J Lee

Sakari Kauppinen

Andreas Petri

Keli Hippen

Pavan Reddy

Charlotte AlbÆk Thrue

Yaping Sun

Dimitrios Papaioannou

The present disclosure relates to recombinant EGFL7, EGFL7 antibodies, and uses thereof.

Recombinant EGFL7, EGFL7 antibodies, and uses thereof

This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.

Materials and methods for modifying the activity of T cells

The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.

Antisense oligomers targeting HOXB-AS3 long non-coding RNA

Described herein are methods of diagnosing a cancer and/or myeloproliferative disorder using microRNAs. Also described are compositions and methods related to cancers and myeloproliferative disorders.

MicroRNA fingerprints during human megakaryocytopoiesis

Described herein is a pharmaceutical composition for treating a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.

Described herein is a method of decreasing expression of HOXA1 in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.

Described herein is a method of decreasing expression of MAFB in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a MAFB gene product where an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the MAFB gene product in the subject.

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer and myeloproliferative disorders. The invention also provides methods of identifying anti-cancer agents.

Growing community of inventors

Columbus, OH, United States of America

Ramiro Garzon